RT Journal Article SR Electronic T1 Clinical Significance of Granzyme B Gene Expression in Pathological Stage II/III Gastric Cancer After Curative Gastrectomy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4537 OP 4542 DO 10.21873/anticanres.17282 VO 44 IS 10 A1 OSHIMA, TAKASHI A1 HASHIMOTO, ITARU A1 HIROSHIMA, YUKIHIKO A1 KIMURA, YAYOI A1 TANABE, MIE A1 NAKAYAMA, YUTA A1 NAGASAWA, SHINSUKE A1 KANEMATSU, KYOHEI A1 AOYAMA, TORU A1 YAMADA, TAKANOBU A1 OGATA, TAKASHI A1 MIYAGI, YOHEI YR 2024 UL http://ar.iiarjournals.org/content/44/10/4537.abstract AB Background/Aim: Granzyme B (GZMB) is mainly produced by natural killer (NK) cells and activated CD8-positive T cells to induce tumor cell apoptosis. We analyzed the significance of GZMB expression in gastric cancer (GC) tissues from patients with pathological (p)Stage II/III GC after curative resection. Patients and Methods: Patients with pStage II/III GC who received curative resection (n=253) were included and the expression levels of GZMB in GC tissues and in the adjacent normal mucosa were measured using quantitative real-time polymerase chain reaction. The expression levels in GC tissues and clinicopathological features and overall survival (OS) were compared in these patients. Results: GZMB expression levels were significantly higher in GC tissues than in the adjacent normal mucosa. GZMB expression levels in GC tissues were not associated with any clinicopathological features. The 5-year OS rate in the high-GZMB expression group was significantly better than that in the low-expression group (5-year survival rate 72.0% vs. 55.7%; p=0.009). Furthermore, on multivariate analysis, high-GZMB expression was an independent factor for better OS (hazard ratio=0.652; 95% confidence interval=0.432-0.987; p=0.043). Conclusion: In patients with locally advanced GC after curative resection, GZMB expression in GC tissue may be a useful prognostic marker.